SAN DIEGO--(BUSINESS WIRE)---- $REVB #EARNINGS--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its three and twelve months ended December 31, 2024 financial results. Corporate Highlights Announced dosing of first patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients Announced start of its PRIME Phase 1b Clinical Study of Gemini in CKD Patients Announced FD.
SAN DIEGO--(BUSINESS WIRE)---- $REVB #GEMINI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced today the Nasdaq Stock Market LLC (“Nasdaq”) formally notified the Company that REVB common stock will continue to be listed and traded on Nasdaq, as Revelation is in compliance with all requirements for continued listing. On January 21, 2025, Revelation announced the commencement.
SAN DIEGO--(BUSINESS WIRE)---- $REVB #GEMINI--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that, on January 28, 2025, the Company will implement a 1-for-16 reverse split of its common stock following approval at its Special Meeting of Stockholders held on January 17, 2025. The reverse stock split will be effective as of the morning of January 28, 2025, and the Company's common stock will trade on a post-split basis at the beginning of trading on the same date under.
SAN DIEGO--(BUSINESS WIRE)---- $REVB #GEMINI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, wants to remind all shareholders to vote their proxies for the January 17, 2025 special meeting of stockholders. In particular, a vote for Proposal 2, the redomicile of the Company from Delaware to Nevada will save the Company at least $200,000.00 per year in franc.
SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, announced today that the United States Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application for Gemini. This game changing milestone allows the Company to initiate its US based Phase 1b clinical study to evaluate the potent.
SAN DIEGO--(BUSINESS WIRE)---- $REVB #FDA--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced it has successfully completed the GMP manufacture of Gemini drug product to support anticipated clinical studies in the United States. GMP compliant manufacturing of Gemini is a pivotal requirement for an Investigational New Drug (IND) ap.
SAN DIEGO--(BUSINESS WIRE)---- $REVB #EARNINGS--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, today reported its three and nine months ended September 30, 2024 financial results. Corporate Highlights Completed GMP manufacture of Gemini clinical drug supply Recei.
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced statistically significant, dose dependent increases of interleukin-10 (IL-10) in response to Gemini treatment, using a high sensitivity analysis. This additional positive data follows the previously reported positive topline data from.
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced safety and biomarker data for its Phase 1 clinical study (RVL-HV02). The primary endpoint to evaluate the safety and tolerability of escalating doses of Gemini was met and a maximum tolerated dose in healthy volunteers was identified.